Table 5 Range of treatment on issues
From: Fuzzy constraint-based agent negotiation framework for doctor-patient shared decision-making
Treatments issues | Cost | Effectiveness | Side-effects | Risk | Convenience |
|---|---|---|---|---|---|
En-high dose ICS/LABAa | 2.7–4.5 | 8–9 | 1–1.5 | 1–2 | 9.5–10 |
En-high dose ICSb + LTRAc | 4.3–6.5 | 7–8 | 2-3 | 1.5–2.5 | 9–9.5 |
En-high dose ICS + sustained-release THPd | 2–4.2 | 6-7 | 6-10 | 2–2.5 | 8–8.5 |
En-high dose ICS/LABA + LTRA | 5.7-7.3 | 9-10 | 5-6 | 1-1 | 7.5–8 |
En-high dose ICS/LABA + sustained-rTHP | 3.5–5 | 9–10 | 6–8 | 1–1 | 7.5–8 |